Intermediate hepatocellular carcinoma: The role of transarterial therapy

Fabrizio Chegai, Antonio Orlacchio, Stefano Merolla, Serena Monti, Lorenzo Mannelli

Research output: Contribution to journalReview article

Abstract

According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients with intermediate stage of HCC represent 20% with a 2-year survival of approximately 50%. Nowadays, transarterial therapies have proved precious in the treatment of hepatic malignancies. During the last years, there were important developments in practiced transarterial therapies and their efficacy is still controversial. The purpose of this review is to discuss in further details these transarterial therapies that have been used to treat cases of HCC.

Original languageEnglish
Pages (from-to)399-408
Number of pages10
JournalHepatic Oncology
Volume2
Issue number4
DOIs
Publication statusPublished - Oct 1 2015

Keywords

  • chemoembolization
  • DEB TACE
  • embolization
  • hepatocellular carcinoma
  • interventional treatment
  • radioembolization
  • transarterial chemo-occlusion
  • transarterial therapy

ASJC Scopus subject areas

  • Hepatology
  • Oncology

Fingerprint Dive into the research topics of 'Intermediate hepatocellular carcinoma: The role of transarterial therapy'. Together they form a unique fingerprint.

  • Cite this